The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tao, R.
Right arrow Articles by Hancock, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tao, R.
Right arrow Articles by Hancock, W. W.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Heart Transplantation
The Journal of Immunology, 2005, 175: 5774-5782.
Copyright © 2005 by The American Association of Immunologists

Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts1

Ran Tao*, Liqing Wang*, Rongxiang Han*, Tao Wang*, Qunrui Ye*, Takasu Honjo{dagger}, Theresa L. Murphy{ddagger}, Kenneth M. Murphy{ddagger} and Wayne W. Hancock2,*

* Division of Transplantation Immunology, Department of Pathology and Laboratory Medicine, Biesecker Pediatric Liver Center, Children’s Hospital of Philadelphia, and University of Pennsylvania School of Medicine, Philadelphia, PA 19104; {dagger} Department of Medical Chemistry and Molecular Biology, Graduate School of Medicine, Kyoto University, Yoshida, Kyoto, Japan; and {ddagger} Department of Pathology and Immunology, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110

Although fully MHC-mismatched murine cardiac allografts are rapidly rejected, allografts mismatched at only MHC class I or class II alleles survive long term; the immunologic basis for the long-term survival of MHC class I- or II-mismatched allografts is unknown. We examined the roles of two recently described inhibitory receptors, B and T lymphocyte attenuator (BTLA) and programmed death-1 (PD-1), in the survival of partially or fully MHC-mismatched allografts using gene-deficient recipients as well as through use of blocking mAbs in wild-type hosts. Partially MHC-mismatched allografts showed strong induction of BTLA, but not PD-1 mRNA and survived long term in wild-type recipients, whereas targeting of BTLA or its ligand, herpesvirus entry mediator, but not PD-1, prompted their rapid rejection. By contrast, fully MHC-mismatched cardiac allografts were acutely rejected in wild-type recipients despite the induction of both BTLA and PD-1. Targeting of PD-1 in several fully MHC-mismatched models accelerated rejection, whereas targeting of BTLA unexpectedly enhanced PD-1 induction by alloreactive CD4 and CD8 T cells and prolonged allograft survival. In vitro studies using allogeneic dendritic cells and T cells showed that at low levels of T cell activation, BTLA expression was primarily induced, but that with increasing degrees of T cell activation, the expression of PD-1 was strongly up-regulated. These data suggest that BTLA and PD-1 exert distinct inhibitory actions in vivo, with the BTLA/herpesvirus entry mediator pathway appearing to dominate in regulating responses against a restricted degree of allogeneic mismatch.




This article has been cited by other articles:


Home page
Am J Clin PatholHome page
H. M'Hidi, M.-L. Thibult, B. Chetaille, F. Rey, R. Bouadallah, R. Nicollas, D. Olive, and L. Xerri
High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Am J Clin Pathol, October 1, 2009; 132(4): 589 - 596.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Sun, N. K. Brown, M. J. Ruddy, M. L. Miller, Y. Lee, Y. Wang, K. M. Murphy, K. Pfeffer, L. Chen, J. Kaye, et al.
B and T Lymphocyte Attenuator Tempers Early Infection Immunity
J. Immunol., August 1, 2009; 183(3): 1946 - 1951.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Crawford and E. J. Wherry
Editorial: Therapeutic potential of targeting BTLA
J. Leukoc. Biol., July 1, 2009; 86(1): 5 - 8.
[Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
W. Truong, W. W. Hancock, J. C. Plester, S. Merani, D. C. Rayner, G. Thangavelu, K. M. Murphy, C. C. Anderson, and A. M. J. Shapiro
BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice
J. Leukoc. Biol., July 1, 2009; 86(1): 41 - 51.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. L. Miller, Y. Sun, and Y.-X. Fu
Cutting Edge: B and T Lymphocyte Attenuator Signaling on NKT Cells Inhibits Cytokine Release and Tissue Injury in Early Immune Responses
J. Immunol., July 1, 2009; 183(1): 32 - 36.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Liu, M. Alexiou, N. Martin-Orozco, Y. Chung, R. I. Nurieva, L. Ma, Q. Tian, G. Kollias, S. Lu, D. Graf, et al.
Cutting Edge: A Critical Role of B and T Lymphocyte Attenuator in Peripheral T Cell Tolerance Induction
J. Immunol., April 15, 2009; 182(8): 4516 - 4520.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. C. Vendel, J. Calemine-Fenaux, A. Izrael-Tomasevic, V. Chauhan, D. Arnott, and D. L. Eaton
B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK
J. Immunol., February 1, 2009; 182(3): 1509 - 1517.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. H. Koehn, M. L. Ford, I. R. Ferrer, K. Borom, S. Gangappa, A. D. Kirk, and C. P. Larsen
PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue
J. Immunol., October 15, 2008; 181(8): 5313 - 5322.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. J. Oestreich, H. Yoon, R. Ahmed, and J. M. Boss
NFATc1 Regulates PD-1 Expression upon T Cell Activation
J. Immunol., October 1, 2008; 181(7): 4832 - 4839.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Deppong, J. M. Degnan, T. L. Murphy, K. M. Murphy, and J. M. Green
B and T Lymphocyte Attenuator Regulates T Cell Survival in the Lung
J. Immunol., September 1, 2008; 181(5): 2973 - 2979.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. W. Steinberg, O. Turovskaya, R. B. Shaikh, G. Kim, D. F. McCole, K. Pfeffer, K. M. Murphy, C. F. Ware, and M. Kronenberg
A crucial role for HVEM and BTLA in preventing intestinal inflammation
J. Exp. Med., June 9, 2008; 205(6): 1463 - 1476.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Tao, L. Wang, K. M. Murphy, C. C. Fraser, and W. W. Hancock
Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells
J. Immunol., May 15, 2008; 180(10): 6649 - 6655.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. A. Nelson, M. D. Fremont, J. R. Sedy, P. S. Norris, C. F. Ware, K. M. Murphy, and D. H. Fremont
Structural Determinants of Herpesvirus Entry Mediator Recognition by Murine B and T Lymphocyte Attenuator
J. Immunol., January 15, 2008; 180(2): 940 - 947.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. De Trez, K. Schneider, K. Potter, N. Droin, J. Fulton, P. S. Norris, S.-w. Ha, Y.-X. Fu, T. Murphy, K. M. Murphy, et al.
The Inhibitory HVEM-BTLA Pathway Counter Regulates Lymphotoxin Receptor Signaling to Achieve Homeostasis of Dendritic Cells
J. Immunol., January 1, 2008; 180(1): 238 - 248.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Lepenies, K. Pfeffer, M. A. Hurchla, T. L. Murphy, K. M. Murphy, J. Oetzel, B. Fleischer, and T. Jacobs
Ligation of B and T Lymphocyte Attenuator Prevents the Genesis of Experimental Cerebral Malaria
J. Immunol., September 15, 2007; 179(6): 4093 - 4100.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
T. Okazaki and T. Honjo
PD-1 and PD-1 ligands: from discovery to clinical application
Int. Immunol., July 2, 2007; (2007) dxm057v1.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Hurchla, J. R. Sedy, and K. M. Murphy
Unexpected Role of B and T Lymphocyte Attenuator in Sustaining Cell Survival during Chronic Allostimulation
J. Immunol., May 15, 2007; 178(10): 6073 - 6082.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Xu, A. S. Flies, D. B. Flies, G. Zhu, S. Anand, S. J. Flies, H. Xu, R. A. Anders, W. W. Hancock, L. Chen, et al.
Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease
Blood, May 1, 2007; 109(9): 4097 - 4104.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Chemnitz, A. R. Lanfranco, I. Braunstein, and J. L. Riley
B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs.
J. Immunol., June 1, 2006; 176(11): 6603 - 6614.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.